HRMY — Harmony Biosciences Holdings Cashflow Statement
0.000.00%
- $1.70bn
- $1.41bn
- $714.73m
- 88
- 77
- 83
- 96
Annual cashflow statement for Harmony Biosciences Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -36.9 | 34.6 | 181 | 129 | 145 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 35.4 | 44.5 | 29.7 | 44.6 | 86.8 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -11.6 | 0.631 | -4.11 | 35 | -7.32 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -2.98 | 98.6 | 144 | 219 | 220 |
Capital Expenditures | -0.002 | -100 | -40.2 | -0.312 | -1.15 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -2 | — | -102 | -46.1 | -66.3 |
Acquisition of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -2 | -100 | -142 | -46.4 | -67.5 |
Financing Cash Flow Items | -36.1 | -31.5 | 0 | -9.36 | -2.5 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 209 | 7.42 | 6.84 | -106 | -11 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 204 | 5.68 | 9.47 | 67.4 | 141 |